跳转至内容
Merck
CN

189826

5-氮杂-2′-脱氧胞苷酸

≥98% (HPLC), liquid, DNA methyltransferase inhibitor, Calbiochem

别名:

InSolution 5-氮杂-2′-脱氧胞苷酸, 地西他滨

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C8H12N4O4
化学文摘社编号:
分子量:
228.21
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

5-氮杂-2′-脱氧胞苷酸, InSolution, ≥98%, DNA methyltransferase inhibitor

SMILES string

N2(C=NC(=N)NC2=O)C1OC(C(C1)O)CO

InChI

1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)

InChI key

XAUDJQYHKZQPEU-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

liquid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
desiccated (hygroscopic)
protect from light

shipped in

ambient

storage temp.

−20°C

Quality Level

Disclaimer

毒性:监管审查(Z)

General description

一种作为DNA甲基转移酶抑制剂的胞嘧啶类似物。在TRAIL抗性细胞系中恢复caspase-8和caspase-10 mRNA和蛋白表达以及TRAIL(肿瘤坏死因子相关凋亡诱导配体)敏感性。也增强HDAC(组蛋白去乙酰化酶)抑制剂诱导的凋亡。另提供该化合物的固体形式(目录号189825)。

Other Notes

Eggert, A., et al. 2001.Cancer Res.61, 1314.
Takebayashi, S., et al. 2001.Biochem.Biophys.Res. Commun.288, 921.
Zhu, W.G., et al. 2001.Cancer Res.61, 1327.
Hopkins-Donaldson, S., et al. 2000.Cancer Res.60, 4315.
Haaf, T. 1995.Pharmacol.Ther.65, 19.
Jones, P.A., and Taylor, S.M.1980.Cell20, 85.

Packaging

用惰性气体包装

Physical form

100 mM(10 mg/438 µl)5-氮杂-2ʹ-脱氧胞苷(目录编号189825)的DMSO溶液。

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

Health hazard

signalword

Danger

hcodes

Hazard Classifications

Muta. 2 - Repr. 1B

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

flash_point_f

188.6 °F - closed cup - (Dimethylsulfoxide)

flash_point_c

87 °C - closed cup - (Dimethylsulfoxide)


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Liangsheng Wang et al.
The Plant journal : for cell and molecular biology, 109(6), 1397-1415 (2021-12-18)
RNA-directed DNA methylation (RdDM) helps to defend plants against invasive nucleic acids. In the canonical form of RdDM, 24-nt small interfering RNAs (siRNAs) are produced by DICER-LIKE 3 (DCL3). The siRNAs are loaded onto ARGONAUTE (AGO) proteins leading ultimately to
Ling-Tong Gao et al.
Cellular and molecular life sciences : CMLS, 80(3), 58-58 (2023-02-07)
The exposure to an unhealthy environment in utero can lead to the occurrence of cardiovascular diseases in the offspring. Glucocorticoids (GC) are essential for normal development and maturation of fetal organs and is a first-line treatment for pregnant women affected
Nanna Jørgensen et al.
International journal of molecular sciences, 21(12) (2020-06-21)
The potential role of human leukocyte antigen (HLA)-G as a target for new cancer immunotherapy drugs has increased the interest in the analysis of mechanisms by which HLA-G expression is regulated, and how the expression can be manipulated. We characterized
Brandt A Nichols et al.
Cancer research, 78(21), 6196-6208 (2018-09-07)
Cancer testis antigens (CTA) are expressed in testis and placenta and anomalously activated in a variety of tumors. The mechanistic contribution of CTAs to neoplastic phenotypes remains largely unknown. Using a chemigenomics approach, we find that the CTA HORMAD1 correlates
Chuannan Fan et al.
Signal transduction and targeted therapy, 7(1), 126-126 (2022-04-29)
Ovo-like transcriptional repressor 1 (OVOL1) is a key mediator of epithelial lineage determination and mesenchymal-epithelial transition (MET). The cytokines transforming growth factor-β (TGF-β) and bone morphogenetic proteins (BMP) control the epithelial-mesenchymal plasticity (EMP) of cancer cells, but whether this occurs

相关内容

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持